MapLight Therapeutics, Inc. (MPLT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, MapLight Therapeutics reported revenue of $0. Net income was -$161.2M, or -$18.56 per diluted share. Operating activities generated -$138.1M of cash, leaving -$138.6M of free cash flow. At fiscal year end, MapLight Therapeutics held $479.5M in total assets against $21.1M in total liabilities, including $46.7M of cash and equivalents.
Open the full interactive MapLight Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
MapLight Therapeutics Key Stats
| Share Price | $7.88 |
|---|---|
| Market Cap | $357.8M |
| 52-Week Range | $7.88 – $39.80 |
| Shares Outstanding | 45.4 million (basic, 2026 Q2) |
MapLight Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$169.1M |
| Pre-Tax Income | -$161.2M |
| Net Income | -$161.2M |
| Diluted EPS | -$18.56 |
MapLight Therapeutics Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income | -$29.4M | -$60.7M | -$60.2M |
| Diluted EPS | -$37.18 | -$1.34 | -$1.32 |
MapLight Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $46.7M |
| Current Assets | $324.7M |
| Total Assets | $479.5M |
| Current Liabilities | $16.2M |
| Total Liabilities | $21.1M |
| Shareholders' Equity | $458.4M |
MapLight Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$138.1M |
| Cash From Investing | -$323.2M |
| Cash From Financing | $469.8M |
| Free Cash Flow | -$138.6M |
Figures from MapLight Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MapLight Therapeutics financials page for every line item.
MapLight Therapeutics Company Profile
| Ticker | MPLT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001770069 |
Frequently Asked Questions
What was MapLight Therapeutics' revenue in fiscal 2025?
MapLight Therapeutics (MPLT) reported revenue of $0 for fiscal 2025.
What was MapLight Therapeutics' net income in fiscal 2025?
MapLight Therapeutics reported net income of -$161.2M for fiscal 2025.
What was MapLight Therapeutics' earnings per share (EPS) in fiscal 2025?
MapLight Therapeutics' diluted EPS was -$18.56 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did MapLight Therapeutics generate in fiscal 2025?
MapLight Therapeutics generated -$138.6M of free cash flow in fiscal 2025.
What was MapLight Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), MapLight Therapeutics reported revenue of $0.
How many shares of MapLight Therapeutics are outstanding?
MapLight Therapeutics reported a weighted average of 45.4 million basic shares outstanding in 2026 Q2.
What is MapLight Therapeutics' market cap?
Based on its latest closing price, MapLight Therapeutics (MPLT) has a market capitalization of about $357.8M.
When does MapLight Therapeutics' fiscal year end?
MapLight Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is MapLight Therapeutics headquartered?
MapLight Therapeutics lists its business address in Redwood City, California in its SEC filings.